Raymond James & Associates Has $3.78 Million Stock Position in Teladoc Health, Inc. (NYSE:TDOC)

Raymond James & Associates reduced its holdings in shares of Teladoc Health, Inc. (NYSE:TDOC) by 23.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 175,610 shares of the health services provider’s stock after selling 52,628 shares during the quarter. Raymond James & Associates’ holdings in Teladoc Health were worth $3,784,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Acadian Asset Management LLC purchased a new position in Teladoc Health during the first quarter worth about $27,000. Dark Forest Capital Management LP boosted its holdings in Teladoc Health by 408.2% during the first quarter. Dark Forest Capital Management LP now owns 1,245 shares of the health services provider’s stock worth $32,000 after purchasing an additional 1,000 shares during the last quarter. Tyler Stone Wealth Management purchased a new position in Teladoc Health during the second quarter worth about $33,000. Quarry LP purchased a new position in Teladoc Health during the first quarter worth about $35,000. Finally, IFP Advisors Inc boosted its holdings in Teladoc Health by 201.5% during the second quarter. IFP Advisors Inc now owns 1,969 shares of the health services provider’s stock worth $50,000 after purchasing an additional 1,316 shares during the last quarter. 76.82% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, CTO Nikolaos P. Nanis sold 2,866 shares of the stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $14.52, for a total transaction of $41,614.32. Following the sale, the chief technology officer now owns 69,850 shares of the company’s stock, valued at approximately $1,014,222. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CTO Nikolaos P. Nanis sold 2,866 shares of the stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $14.52, for a total transaction of $41,614.32. Following the sale, the chief technology officer now owns 69,850 shares of the company’s stock, valued at approximately $1,014,222. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Arnnon Geshuri sold 7,500 shares of the stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $15.06, for a total value of $112,950.00. Following the sale, the insider now directly owns 38,470 shares in the company, valued at approximately $579,358.20. The disclosure for this sale can be found here. In the last quarter, insiders have sold 134,441 shares of company stock valued at $2,025,041. Corporate insiders own 1.63% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. Leerink Partnrs restated a “market perform” rating on shares of Teladoc Health in a report on Monday, February 26th. Royal Bank of Canada lowered their price objective on shares of Teladoc Health from $30.00 to $25.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 21st. SVB Leerink began coverage on shares of Teladoc Health in a research report on Monday, February 26th. They issued a “market perform” rating and a $17.00 price objective on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of Teladoc Health in a research report on Friday, April 5th. Finally, Barclays lowered their price objective on shares of Teladoc Health from $26.00 to $25.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 21st. Eight analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $22.23.

Teladoc Health Price Performance

Teladoc Health stock opened at $14.21 on Friday. The firm has a market capitalization of $2.41 billion, a P/E ratio of -10.60 and a beta of 0.94. Teladoc Health, Inc. has a one year low of $13.59 and a one year high of $30.41. The company has a debt-to-equity ratio of 0.66, a current ratio of 3.54 and a quick ratio of 3.47. The business has a fifty day moving average price of $16.27 and a 200-day moving average price of $18.10.

Teladoc Health (NYSE:TDOC) last issued its quarterly earnings data on Tuesday, February 20th. The health services provider reported ($0.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.05. The business had revenue of $660.50 million for the quarter, compared to analysts’ expectations of $670.79 million. Teladoc Health had a negative return on equity of 9.22% and a negative net margin of 8.47%. The firm’s quarterly revenue was up 3.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.23) EPS. As a group, equities research analysts forecast that Teladoc Health, Inc. will post -1.07 EPS for the current year.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.